Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Lancet
    August 2026
  1. WALKER MC, Murphy MSQ, Scremin Souza SC, Koi-Larbi K, et al
    Pre-eclampsia.
    Lancet. 2026;408:847-860.
    >> Share

    July 2026
  2. SCHWARTZ L, Ahmed E, Palmero A, Ho CWL, et al
    Pregnancy as exclusion criterion in Ebola research: not again.
    Lancet. 2026 Jul 17:S0140-6736(26)01367-X. doi: 10.1016/S0140-6736(26)01367.
    >> Share

    June 2026
  3. PORTNOY A, Burger EA
    HPV vaccination and early declines in cervical cancer deaths.
    Lancet. 2026 Jun 17:S0140-6736(26)01024-X. doi: 10.1016/S0140-6736(26)01024.
    >> Share

  4. SASIENI P, Falcaro M
    Cervical cancer mortality trends following HPV vaccination in England, 2001-24: an analysis of population-based mortality data.
    Lancet. 2026 Jun 17:S0140-6736(26)00918-9. doi: 10.1016/S0140-6736(26)00918.
    >> Share

    May 2026
  5. TEEDE HJ, Khomami MB, Morman R, Laven JSE, et al
    Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.
    Lancet. 2026 May 12:S0140-6736(26)00717-8. doi: 10.1016/S0140-6736(26)00717.
    >> Share

  6. BRISSON M, Drolet M, Gingras G, Laprise JF, et al
    Substantial increases in cervical cancer inequalities worldwide without enhanced human papillomavirus vaccination and screening efforts: a global modelling study.
    Lancet. 2026;407:1726-1737.
    >> Share


  7. Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 15 000 women in 23 randomised trials.
    Lancet. 2026;407:1699-1711.
    >> Share

  8. CLIFFORD GM
    HPV vaccine scale-up is key to curb rising cervical cancer inequalities.
    Lancet. 2026;407:1662-1663.
    >> Share

    April 2026
  9. THE LANCET
    Abortion: the possibilities of progress.
    Lancet. 2026;407:1483.
    >> Share

  10. COLOMBO N, Zsiros E, Parma G, Rulli E, et al
    Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
    Lancet. 2026 Apr 10:S0140-6736(26)00602-1. doi: 10.1016/S0140-6736(26)00602.
    >> Share

  11. LORUSSO D, Gladieff L, O'Malley DM, Kim JW, et al
    Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.
    Lancet. 2026 Apr 10:S0140-6736(26)00462-9. doi: 10.1016/S0140-6736(26)00462.
    >> Share

  12. BIGOT C
    Giving dignity back: obstetric fistula in Somalia.
    Lancet. 2026 Apr 2:S0140-6736(26)00658-6. doi: 10.1016/S0140-6736(26)00658.
    >> Share

    March 2026
  13. HUANG JY, Low FM, Kee MZL, Hopper LN, et al
    More equitable preconception health: paternal life course opportunities for better pregnancy, child, and family outcomes.
    Lancet. 2026 Mar 16:S0140-6736(26)00148-0. doi: 10.1016/S0140-6736(26)00148.
    >> Share

  14. SCHOENAKER D, Hall J, Verbiest S, Nonterah EA, et al
    Measuring progress in pregnancy planning and preconception health.
    Lancet. 2026 Mar 16:S0140-6736(26)00192-3. doi: 10.1016/S0140-6736(26)00192.
    >> Share

  15. CARLIN N
    Cancer in pregnancy: navigating two medical systems.
    Lancet. 2026 Mar 6:S0140-6736(26)00465-4. doi: 10.1016/S0140-6736(26)00465.
    >> Share

    February 2026
  16. LEJEUNE CL, Van Calsteren K, Baert T, Vandecaveye V, et al
    A multidisciplinary management approach to cervical cancer during pregnancy.
    Lancet. 2026 Feb 17:S0140-6736(26)00190-X. doi: 10.1016/S0140-6736(26)00190.
    >> Share

    January 2026
  17. RAY-COQUARD I, Wilson C, Moore K
    The Lancet Commission on Ovarian Cancer: towards equity-driven reform.
    Lancet. 2026 Jan 8:S0140-6736(25)02463-8. doi: 10.1016/S0140-6736(25)02463.
    >> Share

  18. ROBERTS I
    Uterine atony and anaemia in postpartum haemorrhage.
    Lancet. 2026;407:29.
    >> Share

  19. YUNAS I, Devall A, Coomarasamy A
    Uterine atony and anaemia in postpartum haemorrhage - Authors' reply.
    Lancet. 2026;407:29-30.
    >> Share

  20. MANSUKHANI R, Chaudhri R, Bello FA, Muganyizi P, et al
    Uterine atony and anaemia in postpartum haemorrhage.
    Lancet. 2026;407:28-29.
    >> Share

    December 2025
  21. NASH Z, Christmas M, Gronlund T, Hickey M, et al
    Top ten menopause research priorities.
    Lancet. 2025;404:2535-2536.
    >> Share

  22. UBOM AE, Oiwoh SO
    Fetal and maternal outcomes following mpox infection in pregnancy.
    Lancet. 2025 Dec 19:S0140-6736(25)02317-7. doi: 10.1016/S0140-6736(25)02317.
    >> Share

  23. VAKANIAKI EH, Barhishindi I, Mubiala A, Malembaka EB, et al
    Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study.
    Lancet. 2025 Dec 19:S0140-6736(25)02309-8. doi: 10.1016/S0140-6736(25)02309.
    >> Share

  24. MOAYAD L, Mihan A, Peters SAE, Van Spall HGC, et al
    Inclusion of women who are pregnant, lactating, or of reproductive potential in clinical trials: health, ethical, and regulatory considerations.
    Lancet. 2025;406:2858-2864.
    >> Share

  25. TONG S, Cluver CA, Walker SP
    Reducing term pre-eclampsia by 30%: is it possible?
    Lancet. 2025 Dec 4:S0140-6736(25)01672-1. doi: 10.1016/S0140-6736(25)01672.
    >> Share

  26. GOADSBY J, Syngelaki A, Magee LA, von Dadelszen P, et al
    Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial.
    Lancet. 2025 Dec 4:S0140-6736(25)01207-3. doi: 10.1016/S0140-6736(25)01207.
    >> Share

    November 2025
  27. NANA M, Painter R, Williamson C, Nelson-Piercy C, et al
    Hyperemesis gravidarum.
    Lancet. 2025 Nov 13:S0140-6736(25)01454-0. doi: 10.1016/S0140-6736(25)01454.
    >> Share

  28. ANDERSON DJ, Bearak JM, Grimstad FW, Palanee-Phillips T, et al
    Biomedical innovations in contraception: gaps, obstacles, and solutions for sexual and reproductive health.
    Lancet. 2025;406:2119-2132.
    >> Share

    October 2025
  29. SURYAWANSHI H, Gemmell LC, Morgan S, Koustas G, et al
    First clinical pregnancy following AI-based microfluidic sperm detection and recovery in non-obstructive azoospermia.
    Lancet. 2025 Oct 31:S0140-6736(25)01623-X. doi: 10.1016/S0140-6736(25)01623.
    >> Share

  30. ALLEMANI C, Minicozzi P, Morawski B, Lima CA, et al
    Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39
    Lancet. 2025 Oct 22:S0140-6736(25)01383-2. doi: 10.1016/S0140-6736(25)01383.
    >> Share

  31. BEKKER LG, Joseph Davey D, Saidi F
    Two for two: lenacapavir during pregnancy and lactation.
    Lancet. 2025;406:1560-1561.
    >> Share

    August 2025
  32. MCCORMACK M, Eminowicz G, Vaja S, Hackshaw A, et al
    INTERLACE: not a new standard for cervical cancer chemoradiation - Authors' reply.
    Lancet. 2025;406:807.
    >> Share

  33. PETRIC P, Lindegaard JC, Schmid MP, Jurgenliemk-Schulz I, et al
    INTERLACE: not a new standard for cervical cancer chemoradiation.
    Lancet. 2025;406:806-807.
    >> Share


  34. Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
    Lancet. 2025;406:603-614.
    >> Share

  35. LIU T, Lu D, Wu X
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial - Authors' reply.
    Lancet. 2025;406:446.
    >> Share

  36. CHENG C
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial.
    Lancet. 2025;406:445.
    >> Share

  37. HUANG L, We Y, Chen F
    Cadonilimab in advanced cervical cancer: the COMPASSION-16 trial.
    Lancet. 2025;406:445-446.
    >> Share

    July 2025
  38. BRASIL P, Nielsen-Saines K, Guaraldo L, Fuller T, et al
    A decade later, what have we learned from the Zika epidemic in children with intrauterine exposure?
    Lancet. 2025 Jul 3:S0140-6736(25)00826-8. doi: 10.1016/S0140-6736(25)00826.
    >> Share

    June 2025
  39. HARTER P, Marme F
    Targeting the glucocorticoid receptor in relapsed ovarian cancer: a new pathway and standard treatment option in ovarian cancer.
    Lancet. 2025;405:2180-2182.
    >> Share

  40. DE SMIT NS, de Lange ME, Boomsma MF, Huirne JAF, et al
    Current treatment for symptomatic uterine fibroids: available evidence and therapeutic dilemmas.
    Lancet. 2025 Jun 19:S0140-6736(25)00728-7. doi: 10.1016/S0140-6736(25)00728.
    >> Share

  41. FERNANDEZ TURIENZO C, November L, Kamara M, Conteh O, et al
    Community-based mentoring to reduce maternal and perinatal mortality in adolescent pregnancies in Sierra Leone (2YoungLives): a pilot cluster-randomised controlled trial.
    Lancet. 2025 Jun 18:S0140-6736(25)00454-4. doi: 10.1016/S0140-6736(25)00454.
    >> Share

  42. HODNETT E
    A community-based landmark trial to save the lives of pregnant adolescents and their newborns in sub-Saharan Africa.
    Lancet. 2025 Jun 18:S0140-6736(25)00731-7. doi: 10.1016/S0140-6736(25)00731.
    >> Share

  43. OLAWAIYE AB, Gladieff L, O'Malley DM, Kim JW, et al
    Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial.
    Lancet. 2025 Jun 2:S0140-6736(25)01040-2. doi: 10.1016/S0140-6736(25)01040.
    >> Share

    May 2025
  44. SCHOENAKER D, Stephenson J, Chakrabarti S, Alloway L, et al
    Prioritising maternal health must include care before pregnancy.
    Lancet. 2025;405:1903.
    >> Share

  45. GARDOSI J, Ewington LJ, Booth K, Bick D, et al
    Induction of labour versus standard care to prevent shoulder dystocia in fetuses suspected to be large for gestational age in the UK (the Big Baby trial): a multicentre, open-label, randomised controlled trial.
    Lancet. 2025 May 1:S0140-6736(25)00162-X. doi: 10.1016/S0140-6736(25)00162.
    >> Share

    March 2025
  46. LAUDANSKI P
    Natural or artificial menstrual cycle for frozen embryo transfer.
    Lancet. 2025;405:893-894.
    >> Share

  47. MAKAMA M, Vogel JP
    Atosiban and managing women in preterm labour.
    Lancet. 2025 Mar 3:S0140-6736(25)00402-7. doi: 10.1016/S0140-6736(25)00402.
    >> Share

    February 2025
  48. RAHIM MN, Williamson C, Kametas NA, Heneghan MA, et al
    Pregnancy and the liver.
    Lancet. 2025;405:498-513.
    >> Share

  49. HUGHES H
    Endometriosis: an Australian perspective on encouraging change.
    Lancet. 2025;405:378-379.
    >> Share

  50. DANG L, Mi M, Qiao Y, Zhu L, et al
    Eliminating cervical cancer in the Tibetan Plateau.
    Lancet. 2025;405:375-376.
    >> Share

    November 2024
  51. LORUSSO D, Yamada K, Li K, Cerrotta A, et al
    Pembrolizumab for locally advanced cervical cancer - Authors' reply.
    Lancet. 2024;404:2051-2052.
    >> Share

  52. DONG B, Lu Y, Wang Y, Sun P, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050.
    >> Share

  53. SCHMID MP, Petric P, Mahantshetty U, Kirisits C, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2050-2051.
    >> Share

  54. KAMRAVA M, Beriwal S
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049.
    >> Share

  55. MURAKAMI N, Okonogi N, Terao Y, Shikama N, et al
    Pembrolizumab for locally advanced cervical cancer.
    Lancet. 2024;404:2049-2050.
    >> Share


  56. Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    >> Share

    October 2024
  57. MCCORMACK M, Eminowicz G, Gallardo D, Diez P, et al
    Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial.
    Lancet. 2024;404:1525-1535.
    >> Share

  58. DUSKA LR, Randall LM
    Progress in the treatment paradigms for locally advanced cervical cancer.
    Lancet. 2024;404:1494-1496.
    >> Share

  59. WU X, Sun Y, Yang H, Wang J, et al
    Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
    Lancet. 2024 Oct 15:S0140-6736(24)02135-4. doi: 10.1016/S0140-6736(24)02135.
    >> Share

  60. SUN C, Ma D
    Embracing more treatment choices for metastatic, recurrent, or persistent cervical cancer.
    Lancet. 2024 Oct 15:S0140-6736(24)02196-2. doi: 10.1016/S0140-6736(24)02196.
    >> Share

  61. THE LANCET
    Endometriosis: addressing the roots of slow progress.
    Lancet. 2024;404:1279.
    >> Share

    September 2024
  62. SHARP G, Randhawa A, Fernando AN
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01710-0. doi: 10.1016/S0140-6736(24)01710.
    >> Share

  63. BROWN L, Hunter MS, Crandall CJ, Connors HJ, et al
    Reflections on The Lancet menopause Series - Authors' reply.
    Lancet. 2024 Sep 25:S0140-6736(24)01712-4. doi: 10.1016/S0140-6736(24)01712.
    >> Share

  64. STUCKEY BGA
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01709-4. doi: 10.1016/S0140-6736(24)01709.
    >> Share

  65. XIAO Y, Shen M, Chen X
    Reflections on The Lancet menopause Series.
    Lancet. 2024 Sep 25:S0140-6736(24)01711-2. doi: 10.1016/S0140-6736(24)01711.
    >> Share

  66. GENNIGENS C
    Hope emerging in the locally advanced cervical cancer landscape.
    Lancet. 2024 Sep 13:S0140-6736(24)01918-4. doi: 10.1016/S0140-6736(24)01918.
    >> Share

  67. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-
    Lancet. 2024 Sep 13:S0140-6736(24)01808-7. doi: 10.1016/S0140-6736(24)01808.
    >> Share

    August 2024
  68. RYDELIUS J, Hognert H, Kopp-Kallner H, Brandell K, et al
    First dose of misoprostol administration at home or in hospital for medical abortion between 12-22 gestational weeks in Sweden (PRIMA): a multicentre, open-label, randomised controlled trial.
    Lancet. 2024;404:864-873.
    >> Share

  69. MOSESON H, Gerdts C
    Expanding access, reducing burdens, and improving person-centred care in abortion.
    Lancet. 2024;404:826-827.
    >> Share

  70. FIGUERAS F, Rial-Crestelo M, Gratacos E
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial - Authors' reply.
    Lancet. 2024;404:751-752.
    >> Share

  71. GILES-CLARK HJ, Rolnik DL, Hodges RJ, Skinner SM, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750.
    >> Share

  72. BACON I, Hezelgrave NL, Cerdeira AS, Mylrea-Foley B, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:750-751.
    >> Share

  73. KAMIHARA Y, Nagase H, Ishikawa H
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749-750.
    >> Share

  74. MEIJERINK L, Terstappen F, Depmann M, Bekker M, et al
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:749.
    >> Share

  75. BORNSTEIN E, Vintzileos A
    Cerebroplacental ratio in low-risk pregnancies: the RATIO37 trial.
    Lancet. 2024;404:748-749.
    >> Share

  76. WEI F, Georges D, Man I, Baussano I, et al
    Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature.
    Lancet. 2024;404:435-444.
    >> Share

  77. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    >> Share

    July 2024
  78. ALVES L
    New abortion bill in Brazil sparks backlash.
    Lancet. 2024;404:17.
    >> Share

    June 2024
  79. HO VNA, Pham TD, Nguyen NT, Wang R, et al
    Livebirth rate after one frozen embryo transfer in ovulatory women starting with natural, modified natural, or artificial endometrial preparation in Viet Nam: an open-label randomised controlled trial.
    Lancet. 2024 Jun 26:S0140-6736(24)00756-6. doi: 10.1016/S0140-6736(24)00756.
    >> Share

  80. JAFFE S
    US Supreme Court protects access to abortion medication.
    Lancet. 2024;403:2679-2680.
    >> Share

  81. SWEETING A, Hannah W, Backman H, Catalano P, et al
    Epidemiology and management of gestational diabetes.
    Lancet. 2024 Jun 18:S0140-6736(24)00825-0. doi: 10.1016/S0140-6736(24)00825.
    >> Share

  82. HIVERT MF, Backman H, Benhalima K, Catalano P, et al
    Pathophysiology from preconception, during pregnancy, and beyond.
    Lancet. 2024 Jun 18:S0140-6736(24)00827-4. doi: 10.1016/S0140-6736(24)00827.
    >> Share

    May 2024
  83. SAMARASINGHE SNS, Leca B, Alabdulkader S, Dimitriadis GK, et al
    Bariatric surgery for spontaneous ovulation in women living with polycystic ovary syndrome: the BAMBINI multicentre, open-label, randomised controlled trial.
    Lancet. 2024 May 20:S0140-6736(24)00538-5. doi: 10.1016/S0140-6736(24)00538.
    >> Share

  84. MORIN-PAPUNEN L
    Bariatric surgery in women with PCOS and obesity.
    Lancet. 2024 May 20:S0140-6736(24)00811-0. doi: 10.1016/S0140-6736(24)00811.
    >> Share

    April 2024
  85. STRAND TA, McCann A, Kvestad I, Chandyo RK, et al
    Vitamin B12 deficiency in pregnant women - Authors' reply.
    Lancet. 2024;403:1450.
    >> Share

  86. SEN S
    Vitamin B12 deficiency in pregnant women.
    Lancet. 2024;403:1449-1450.
    >> Share

    March 2024
  87. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
    Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
    Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
    >> Share

  88. GAILLARD R
    Optimising gestational weight gain among pregnant women with obesity.
    Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
    >> Share

  89. LORUSSO D, Xiang Y, Hasegawa K, Scambia G, et al
    Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial.
    Lancet. 2024 Mar 20:S0140-6736(24)00317-9. doi: 10.1016/S0140-6736(24)00317.
    >> Share

  90. TEWARI KS, Monk BJ
    Immunotherapy plus chemoradiotherapy in cervical cancer management.
    Lancet. 2024 Mar 20:S0140-6736(24)00468-9. doi: 10.1016/S0140-6736(24)00468.
    >> Share

  91. HEISLER M, Mitchell N, Arey W, Erenberg M, et al
    US abortion bans should not pre-empt the duty to provide life-saving abortion care to pregnant patients in medical emergencies.
    Lancet. 2024 Mar 19:S0140-6736(24)00551-8. doi: 10.1016/S0140-6736(24)00551.
    >> Share

  92. DADOUN S, Demmler-Harrison GJ, Ketwaroo P, Castro EC, et al
    Congenital toxoplasmosis of the brain caused by infection in late pregnancy.
    Lancet. 2024;403:1081-1082.
    >> Share

  93. MISHRA GD, Davies MC, Hillman S, Chung HF, et al
    Optimising health after early menopause.
    Lancet. 2024;403:958-968.
    >> Share

  94. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    >> Share

  95. BROWN L, Hunter MS, Chen R, Crandall CJ, et al
    Promoting good mental health over the menopause transition.
    Lancet. 2024;403:969-983.
    >> Share

  96. HICKEY M, LaCroix AZ, Doust J, Mishra GD, et al
    An empowerment model for managing menopause.
    Lancet. 2024;403:947-957.
    >> Share

  97. HAWKES P, Scott J, Hickey M
    500 Strong: celebrating older women's bodies in menopause and beyond.
    Lancet. 2024;403:894-903.
    >> Share

  98. SAMARASEKERA U
    Martha Hickey: responding to the complexity of menopause.
    Lancet. 2024;403:893.
    >> Share

  99. THE LANCET
    Time for a balanced conversation about menopause.
    Lancet. 2024;403:877.
    >> Share

  100. NIELSEN OH, Gubatan JM, Kolho KL, Streett SE, et al
    Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation.
    Lancet. 2024 Mar 5:S0140-6736(24)00052-7. doi: 10.1016/S0140-6736(24)00052.
    >> Share

  101. ZAROCOSTAS J
    Renewed calls to scale-up cervical cancer screening.
    Lancet. 2024;403:797.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016